HMG-CoA reductase and farnesyl-pyrophosphate synthase inhibitors for the treatment of conditions related to prenylated proteins in cells
US8518914B2 · kind B2 · utility
1Cited by
0References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 5, 2007 |
| Grant date | Aug 27, 2013 |
| Priority date | — |
| Expiry date | Oct 5, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61Q19/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the use of a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and of a farnesyl-pyrophosphate synthase inhibitor, or of one of their associated physiologically acceptable salts, in the preparation of a composition, particularly a pharmaceutical composition, for use in the treatment of human or animal, pathological or nonpathological situations related to the accumulation and/or the persistence of prenylated proteins in cells, such as during progeria (Hutchinson-Gilford syndrome), restrictive dermopathy or physiological aging.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.